Moderna working on third vaccine dose to combat COVID-19 variants

Moderna working on third vaccine dose to combat COVID-19 variants

J&J announced on Friday its COVID-19 vaccine was 72% effective at curbing symptomatic infections in U.S. trials, while Moderna's was more than 94% effective at the same.

The UK has made a decision to delay administering second doses by up to 12 weeks in order to vaccinate as many people as possible.

Johnson & Johnson's Janssen Pharmaceutical Companies announced on Friday its single-dose COVID-19 vaccine is 72% effective in the preventing moderate to severe COVID-19.

"We will have to be nimble to adjust and make vaccine against whatever mutant is prevalent at the present time", he told reporters. "So I think it is a very, very important vaccine", said Dr. Dougherty.

Effectiveness: 89 percent effective after both doses.

Their efficacy rates, which exceeded 90 percent in clinical trials, were reported prior to growing concerns over what appears to be more contagious variants initially detected in Britain and South Africa.

One of the scientists who helped develop Moderna's COVID-19 vaccine applauded Johnson & Johnson's new trial results, even though they are not as stellar as her own.

Six-point plan released by province to fight COVID-19 variants
Ontario has detected 52 cases of the particularly concerning variant first discovered in the United Kingdom since December 26. Anyone who refuses to get the mandatory test will be fined $750, according to Ontario's Health Minister Christine Elliott.

"As manufacturing ramps up, we're going to be able to have more sites that are able to distribute the vaccine that won't need those freezers that are required for the [Pfizer and Moderna] vaccines", said Dr. Dougherty.

Corbett was instrumental in developing Moderna's new mRNA COVID-19 vaccine, which (along with Pfizer's vaccine) is one of two vaccines authorized for emergency use to fight the pandemic in the US.

Both Fauci and Walensky expressed concern about the spread of coronavirus variants in the USA, with the latest example being a mutation first seen in South Africa that has now been reported in two people in SC.

Moderna, a USA biotechnology company, said earlier this week that its vaccine is expected to be protective against the variants, but that it is advancing a vaccine booster candidate against the South African strain into preclinical studies.

Two more vaccines from American companies are nearing the stage where the FDA can evaluate them for approval.

Also, the Occupational Safety and Health Administration has issued stronger COVID-19 safety measures for workers this week, Slavitt said. Also, all packages of the Pfizer vaccine now getting shipped out contain low dead-volume syringes to maximize the number of doses that can be obtained from each vial, Slavitt said.

Related Articles